Form 8-K

8-K — Solventum Corp

Accession: 0001964738-26-000045

Filed: 2026-08-05

Period: 2026-08-05

CIK: 0001964738

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — solv-20260805.htm (Primary)

EX-99.1 (q22026-8kerexx991.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: solv-20260805.htm · Sequence: 1

solv-20260805

FALSE000196473800019647382026-08-052026-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 5, 2026

SOLVENTUM CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Delaware

File No. 001-41968

92-2008841

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

1750 Yankee Doodle Road, Eagan, Minnesota

55121

(Address of Principal Executive Offices)

(Zip Code)

(Registrant’s Telephone Number, Including Area Code) (651) 733-1110

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $.01 Per Share

SOLV

New York Stock Exchange

Securities registered pursuant to section 12(g) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition

On August 5, 2026, Solventum issued a press release reporting second-quarter 2026 financial results (attached hereunder as Exhibit 99.1 and incorporated herein by reference).

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit Number Description

99.1

Press Release, dated as of August 5, 2026, of Solventum Corporation (furnished pursuant to Item 2.02 hereof)

104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SOLVENTUM CORPORATION

By:

/s/ Wayde McMillan

Wayde McMillan

Executive Vice President and Chief Financial Officer (Principal Financial Officer)

Dated: August 5, 2026

EX-99.1

Filename: q22026-8kerexx991.htm · Sequence: 2

Document

Exhibit 99.1

Solventum Reports Second Quarter 2026 Financial Results

•Reported sales increased 2.2%; organic sales increased 9.5%

•Announces intent to separate its Health Information Systems business segment

•Increases full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow

EAGAN, Minn., August 5, 2026 – Solventum (NYSE: SOLV) today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Highlights

•Sales of $2.2 billion, increased 2.2% on a reported basis; an increase of 9.5% on an organic basis

•GAAP diluted earnings per share of $0.53; adjusted diluted earnings per share of $2.55, a 50.9% increase

•Operating cash flow of $227 million; free cash flow of $144 million

“The Solventum team delivered another quarter of strong execution with results ahead of our expectations while continuing to advance our transformation,” said Bryan Hanson, chief executive officer of Solventum. “We remain on track to achieve our long-term objectives as we build a more focused, dedicated MedTech company, well-positioned to create long-term shareholder value.”

Second Quarter and First Six Months 2026 Financial Results

Three months ended June 30, Six Months Ended June 30,

(Dollars in millions, except per share amounts) 2026 2025 Year-over-year change 2026 2025 Year over year change

Net sales $ 2,209 $ 2,161 2.2 % $ 4,216 $ 4,231 (0.4) %

Selling, general and administrative expenses $ 927 $ 772 20.1 % $ 1,754 $ 1,541 13.8 %

Research and development expenses $ 178 $ 189 (5.8) % $ 367 $ 381 (3.7) %

Operating income margin 8.2 % 9.9 % (170) bps 6.2 % 8.7 % (250) bps

Adjusted operating income margin1

28.4 % 21.9 % 650 bps 24.2 % 20.8 % 340 bps

Net income $ 92 $ 90 2.2 % $ 105 $ 227 (53.7) %

Diluted earnings per share $ 0.53 $ 0.51 3.9 % $ 0.60 $ 1.30 (53.8) %

Adjusted diluted earnings per share1

$ 2.55 $ 1.69 50.9 % $ 4.02 $ 3.03 32.7 %

Net cash provided by (used in) operating activities $ 227 $ 169 34.3 % $ 38 $ 198 (80.8) %

Free cash flow1

$ 144 $ 59 144.1 % $ (129) $ (21) (514.3) %

1 Represents non-GAAP financial measure; see the “Non-GAAP Financial Measures” section for applicable information.

Discussion of Second Quarter Results

All comparisons are to the prior year period unless otherwise noted

•Organic sales growth of +9.5% in the quarter reflects strong performance across all reportable segments, primarily driven by volume and product mix and including the expected benefit of advance orders placed ahead of ERP cutovers.

•GAAP and adjusted gross margin both increased, driven by IEEPA tariff refund.

•GAAP selling, general and administrative expenses increased primarily due to higher costs associated with separation activities and net legal costs. Adjusted SG&A as a percent of sales was 26.0%, a decrease of 130 bps vs. prior year.

•GAAP operating income margin decreased, primarily driven by net legal costs, separation and restructuring costs. Adjusted operating income margin increased primarily due to a combination of IEEPA tariff refund and ERP-timing benefit.

•Operating cash flow for the quarter was $227 million and free cash flow was $144 million, ahead of expectations driven by timing of tax payments and insurance proceeds.

Other Business and Operational Highlights

•Announced the intent to separate its Health Information Systems business segment as part of the portfolio optimization phase of its transformation strategy. The proposed separation is expected to strengthen Solventum’s focus as a dedicated MedTech company while enabling both businesses to pursue distinct growth and innovation priorities.

•The Solventum Foundation announced a $350,000 grant to America’s ToothFairy to expand access to oral health screenings, dental education and fluoride treatment for more than 100,000 children and caregivers in underserved communities over the next year.

•For the second year in a row, named a Best Company to Work For by U.S. News & World Report in the categories of ‘Health Care and Research’ and ‘Midwest.’

Segment and Total Company Net Sales for Second Quarter and First Six Months*

Three months ended June 30, Increase/(Decrease)

(Dollars in millions) 2026 2025 Reported growth Currency impact

Constant currency2

Other3

Organic growth

Advanced Wound Care $ 537 $ 467 14.9 % 1.0 % 13.9 % 6.8 % 7.1 %

Infection Prevention and Surgical Solutions 836 750 11.3 1.2 10.1 — 10.1

MedSurg 1,372 1,218 12.7 1.1 11.6 2.7 8.9

Dental Solutions 396 338 17.0 1.8 15.2 — 15.2

Health Information Systems 354 339 4.4 0.2 4.2 (1.2) 5.4

Total reportable segment net sales 2,122 1,895

Purification and Filtration — 189 NM NM NM NM NM

All Other4

87 77 11.8 1.2 10.6 — 10.6

Total Company $ 2,209 $ 2,161 2.2 % 1.0 % 1.2 % (8.3) % 9.5 %

Six months ended June 30, Increase/(Decrease)

(Dollars in millions) 2026 2025 Reported growth Currency impact

Constant currency2

Other3

Organic growth

Advanced Wound Care $ 1,034 $ 915 12.9 % 1.7 % 11.2 % 6.6 % 4.6 %

Infection Prevention and Surgical Solutions 1,573 1,460 7.7 2.2 5.5 — 5.5

MedSurg 2,607 2,375 9.7 2.0 7.7 2.6 5.1

Dental Solutions 750 667 12.5 3.1 9.4 — 9.4

Health Information Systems 696 667 4.3 0.5 3.8 (1.3) 5.1

Total reportable segment net sales 4,053 3,709

Purification and Filtration — 369 NM NM NM NM NM

All Other4

163 153 6.4 1.7 4.7 — 4.7

Total Company $ 4,216 $ 4,231 (0.4) % 1.8 % (2.2) % (8.0) % 5.8 %

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. “NM” reflects results considered not meaningful due to sale of the Purification and Filtration business in September 2025.

2 Constant currency represents the change in net sales absent the impact on sales from foreign currency translation.

3 Other represents sales impact from acquisitions and divestitures measured separately for the first 12 months post-transaction. Acquisitions include sales from the December 2025 acquisition of Acera. Divestitures primarily represents lost sales from the Company’s Purification and Filtration business that was sold in September 2025.

4 All Other includes the Drinking Water business, which was previously reported within Purification and Filtration, and sales related to product supplied to 3M and other supply agreements related to legacy 3M business and assumed by the Company at Spin-Off.

Full-Year 2026 Guidance

Solventum is updating its full year 2026 guidance as follows:

•Increased organic sales growth range to +2.5% to +3.0% (+3.5% to +4.0% excluding ~100 bps of SKU exit impact); from prior range of +2.0% to +3.0%

•Increased adjusted EPS range to $7.10 to $7.20; from the upper end of prior range of $6.40 to $6.60

•Increased free cash flow to be in the range of $200 million to $300 million; from prior estimate of ~$200M

Organic sales, adjusted diluted EPS and free cash flow amounts included in Solventum’s full-year guidance are non-GAAP financial measures. Solventum does not provide reconciliations of the forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items, such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items.

See the “Non-GAAP Financial Measures” section for explanations of our non-GAAP financial measures.

Earnings Conference Call

Solventum will host a conference call today, August 5, at 4:30 p.m. Eastern Time to discuss its second quarter financial results and fiscal year 2026 outlook. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers, using the conference ID 6342275.

A replay of the webcast, along with the earnings press release, slides highlighting the results and supplemental financial disclosures, will also be available at the same link on the Investor Relations section of the Company’s website.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934 that are subject to risks and uncertainties. Solventum intends the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in those sections. Forward-looking statements include all statements that are not historical facts, but instead represent only Solventum’s beliefs regarding future goals, plans and expectations about its prospects for the future and other events, many of which, by their nature, are inherently uncertain and outside of Solventum’s control. Forward-looking statements include those containing such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “guidance,” “intends,” “may,” “outlook,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “sees,” “should,” “targets,” “will,” “would,” or other words of similar meaning in connection with any discussion of future operating or financial performance, business plans or prospects, Solventum’s review of strategic alternatives for its health information systems business, or the potential benefits of any such strategic alternatives or transaction.

Among the factors that could cause actual results to differ materially from those described in our forward-looking statements are the following: (1) whether Solventum will be able to identify or develop any strategic alternatives for Solventum’s health information systems business; (2) Solventum’s ability to execute on material aspects of any strategic alternatives that are identified and pursued; (3) whether Solventum can actually achieve the potential benefits of any strategic alternatives; (4) the occurrence of any event, change or other circumstances that could give rise to the abandonment of the review of strategic alternatives or pursuit of a different structure or strategic alternative; (5) uncertainties as to the timing of the review of strategic alternatives; (6) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises and other events beyond Solventum’s control; (7) operational execution risks; (8) damage to Solventum’s reputation or its brands; (9) risks from acquisitions, strategic alliances, divestitures and other strategic events; (10) Solventum’s business dealings involving third-party partners in various markets; (11) Solventum’s ability to access the capital and credit markets and changes in Solventum’s credit ratings; (12) exposure to interest rate and currency risks; (13) the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (14) reduction in customers’ research budgets or government funding; (15) the timing and market acceptance of Solventum’s new product and service offerings; (16) ongoing working relationships with certain key healthcare professionals; (17) changes in reimbursement practices of governments or private payers or

other cost containment measures; (18) Solventum’s ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions and disruptive factors; (19) legal and regulatory proceedings and legal compliance risks (including third-party risks) with regards to antitrust, FCPA and other anti-bribery laws, environmental laws, anti-kickback and false claims laws, privacy laws, product liability claims, tax laws, and other laws and regulations in the United States and other countries in which Solventum operates; (20) potential liabilities related to per-and polyfluoroalkyl substances, collectively known as “PFAS”; (21) risks related to the highly regulated environment in which Solventum operates; (22) risks associated with product liability claims; (23) climate change and measures to address climate change; (24) security breaches and other disruptions to information technology infrastructure; (25) artificial intelligence risks; (26) Solventum’s failure to obtain, maintain, protect or effectively enforce its intellectual property rights; (27) pension and postretirement obligation liabilities; (28) Solventum's separation from 3M and performance as a standalone company, including the tax-free nature of the spin and its ability to execute on its short- and long-range plans and capital allocation strategies; and (29) restructuring programs, and other risks and uncertainties described in Solventum’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

The above list is not exhaustive or necessarily set forth in the order of importance. Forward-looking statements are based on certain assumptions and expectations of future events and trends, and actual future results and trends may differ materially from historical results or those reflected in any such forward-looking statements depending on a variety of factors. A further description of these factors is located under “Cautionary Note Concerning Forward-Looking Statements” and “Risk Factors” in Solventum’s periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information, future events or otherwise, except as required by applicable law.

Non-GAAP Financial Measures

In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adjusted measures are not in accordance with, nor are they a substitute for, GAAP measures. These non-GAAP financial measures are supplemental measures of our performance and our liquidity that we believe help investors understand our underlying business performance and Solventum uses these measures as an indication of the strength of Solventum and its ability to generate cash.

Solventum calculates forward-looking non-GAAP financial measures, including organic sales growth, adjusted gross margin, adjusted operating income, adjusted operating income margin, adjusted effective tax rate, adjusted diluted earnings per share and free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. Solventum does not provide reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable GAAP measures as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items. The timing and amounts of these items are uncertain and could have a material impact on Solventum’s results in accordance with GAAP.

The Q2 2026 financial statements and financial information, including reconciliations of non-GAAP financial measures, are available on Solventum’s website: investors.solventum.com.

About Solventum

At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients’ lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

Solventum Investor Contact:

investors@solventum.com

Solventum Media Contact:

news@solventum.com

Solventum Corporation

CONDENSED CONSOLIDATED STATEMENTS OF INCOME*

(Dollars in millions, except per-share data)

(Unaudited)

Three months ended June 30, Six months ended June 30,

2026 2025 2026 2025

Net sales of product $ 1,698 $ 1,668 $ 3,211 $ 3,265

Net sales of software and rentals 511 493 1,005 966

Total net sales 2,209 2,161 4,216 4,231

Cost of product 807 865 1,603 1,700

Cost of software and rentals 116 121 231 242

Gross profit 1,286 1,175 2,382 2,289

Selling, general and administrative expenses 927 772 1,754 1,541

Research and development expenses 178 189 367 381

Operating income 181 214 262 367

Interest expense, net 64 103 125 207

Other expense (income), net 9 8 13 19

Income before income taxes 108 103 123 141

Provision for (benefit from) income taxes 15 13 19 (86)

Net income $ 92 $ 90 $ 105 $ 227

Earnings per share:

Basic earnings per share $ 0.53 $ 0.52 $ 0.60 $ 1.31

Diluted earnings per share 0.53 0.51 0.60 1.30

Weighted-average number of shares outstanding:

Basic 172.7 174.1 173.5 173.9

Diluted 173.3 175.2 174.4 175.0

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

Solventum Corporation

CONDENSED CONSOLIDATED BALANCE SHEETS*

(Dollars in millions, except per-share data)

(Unaudited)

June 30, December 31,

2026 2025

Assets

Current assets

Cash and cash equivalents $ 403 $ 878

Accounts receivable — net of allowances of $82 and $87

1,310 1,034

Due from related parties 122 150

Inventories

Finished goods 573 636

Work in process 218 201

Raw materials and supplies 249 229

Total inventories 1,040 1,066

Other current assets 865 731

Total current assets 3,741 3,859

Property, plant and equipment — net 1,565 1,326

Goodwill 5,626 5,704

Intangible assets — net 2,408 2,592

Other assets 904 814

Total assets $ 14,243 $ 14,294

Liabilities

Current liabilities

Short-term borrowings and current portion of long-term debt $ 506 $ —

Accounts payable 701 687

Due to related parties 331 435

Unearned revenue 596 621

Other current liabilities 1,528 1,393

Total current liabilities 3,663 3,136

Long-term debt 4,573 5,035

Pension and postretirement benefits 358 363

Deferred income taxes 157 164

Finance leases 207 —

Other liabilities 486 547

Total liabilities $ 9,443 $ 9,245

Equity

Common stock, par value $0.01 per share, 750,000,000 shares authorized

$ 2 $ 2

Shares - June 30, 2026: issued: 174,889,899; outstanding: 170,113,551

Shares - December 31, 2025: issued and outstanding: 173,490,864

Additional paid-in capital 3,919 3,876

Retained earnings 1,902 1,797

Treasury stock, at cost (355) —

Shares - June 30, 2026: 4,776,348

Shares - December 31, 2025: —

Accumulated other comprehensive income (loss) (669) (625)

Total equity 4,800 5,049

Total liabilities and equity $ 14,243 $ 14,294

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

Solventum Corporation

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS*

(Dollars in millions)

(Unaudited)

Six months ended June 30,

2026 2025

Cash flows from operating activities

Net income $ 105 $ 227

Adjustments to reconcile net income to net cash provided by (used in) operating activities

Depreciation and amortization 268 251

Pension and postretirement benefit expense 27 32

Stock-based compensation expense 89 83

Deferred income taxes (88) (177)

Changes in assets and liabilities

Accounts receivable (286) (15)

Due from related parties 27 4

Inventories 18 (77)

Accounts payable 26 23

Due to related parties (117) (6)

Accrued compensation (101) (47)

All other operating activities — net 68 (100)

Net cash provided by operating activities 38 198

Cash flows from investing activities

Purchases of property, plant and equipment (167) (219)

Other — net 3 (5)

Net cash used in investing activities (164) (224)

Cash flows from financing activities

Repayment of debt — (200)

Proceeds from debt, net of issuance costs 46 —

Net transfers from (to) 3M 2 (30)

Purchases of treasury stock (355) —

Other — net (44) (19)

Net cash used in financing activities (350) (249)

Effect of exchange rate changes on cash and cash equivalents 1 7

Net increase (decrease) in cash and cash equivalents (475) (268)

Cash and cash equivalents at beginning of period 878 762

Less: Cash and cash equivalents within held for sale — (2)

Cash and cash equivalents at end of period $ 403 $ 492

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

Solventum Corporation

BUSINESS SEGMENTS*

(Unaudited)

The Company’s operating activities are primarily managed through three segments: MedSurg, Dental Solutions and Health Information Systems.

•MedSurg provides:

◦Advanced wound care products such as negative pressure wound therapy, advanced wound dressings, advanced skin care and synthetic tissue matrices; and

◦Infection prevention and surgical solutions products, such as IV site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer (“OEM”).

•Dental Solutions provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents that span the “life of the tooth,” including products designed for preventative dental care, direct and indirect restoration, and broad orthodontic needs.

•Health Information Systems provides healthcare systems with software solutions — including computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms — that are designed to eliminate revenue cycle waste, create more time for patient care, and support value-based care.

Purification and Filtration consists of filters and membranes for biopharmaceutical and medical technologies, as well as microelectronics and food and beverage that were reported prior to the sale of the business in September 2025.

All Other primarily consists of our drinking water filtration business that was retained after the sale of the Purification and Filtration Business. All Other also includes sales and cost of sales related to our agreements to supply 3M and other supply agreements assumed by the Company at Spin-Off related to legacy 3M businesses, which were historically included within Corporate and Unallocated.

BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES*

Three months ended June 30, 2026 Three months ended June 30, 2025

(Dollars in millions) Net sales Operating income Operating margin % Net sales Operating income Operating margin %

Advanced Wound Care $ 537 $ 467

Infection Prevention and Surgical Solutions 836 750

MedSurg 1,372 $ 355 25.8 % 1,218 $ 210 17.3 %

Dental Solutions 396 131 33.0 338 96 28.5

Health Information Systems 354 145 41.0 339 120 35.5

Total reportable segment net sales and operating income 2,122 631 1,895 426

Purification and Filtration — — NM 189 43 23.1

All Other 87 19 21.4 77 8 10.3

Amortization expense (90) (78)

Corporate and unallocated (378) (185)

Total Company $ 2,209 $ 181 8.2 % $ 2,161 $ 214 9.9 %

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

Solventum Corporation

BUSINESS SEGMENTS – (CONTINUED)*

(Unaudited)

BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES*

Six months ended June 30, 2026

Six months ended June 30, 2025

(Dollars in millions) Net sales Operating income Operating margin % Net sales Operating income Operating margin %

Advanced Wound Care $ 1,034 $ 915

Infection Prevention and Surgical Solutions 1,573 1,460

MedSurg 2,607 $ 516 19.8 % 2,375 416 17.5 %

Dental Solutions 750 218 29.0 667 175 26.2

Health Information Systems 696 276 39.6 667 229 34.3

Total reportable segment net sales and operating income 4,053 1,009 3,709 820

Purification and Filtration — — NM 369 70 19.2

All Other 163 30 18.6 153 19 12.7

Amortization expense (181) (159)

Corporate and unallocated (597) (384)

Total Company $ 4,216 $ 262 6.2 % $ 4,231 367 8.7 %

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

Solventum Corporation

SUPPLEMENTAL FINANCIAL INFORMATION

NON-GAAP MEASURES

(Unaudited)

In addition to reporting financial results in accordance with U.S. GAAP, the Company uses non-GAAP financial measures to supplement the financial measures prepared in accordance with U.S. GAAP. These include (1) adjusted gross margin, adjusted operating income and adjusted operating income margin, (2) adjusted diluted earnings per share, and (3) free cash flow. Management believes that these non-GAAP financial measures are useful in evaluating current performance and focusing management on our underlying operational results.

There are limitations to the use of the non-GAAP financial measures presented in this information statement. These non-GAAP financial measures are not prepared in accordance with U.S. GAAP nor do they have any standardized meaning under U.S. GAAP. In addition, other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way we calculate such measures. Accordingly, our non-GAAP financial measures may not be comparable to such similarly titled non-GAAP financial measures used by other companies. Management cautions you not to place undue reliance on these non-GAAP financial measures, but instead to consider them with the most directly comparable U.S. GAAP measure. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation. These non-GAAP financial measures should be considered supplements to, not substitutes for, or superior to, the corresponding financial measures calculated in accordance with U.S. GAAP.

The tables below reconcile our non-GAAP financial measures to the nearest financial measure that is in accordance with U.S. GAAP for the periods presented.

Adjusted Gross Margin, Adjusted Operating Income, Adjusted Operating Income Margin and Adjusted Earnings Per Share (Non-GAAP measures)

Adjusted gross margin, adjusted operating income and adjusted operating income margin are not defined under U.S. GAAP. Therefore, they should not be considered a substitute for earnings data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. Solventum defines adjusted gross margin as gross margin excluding the effects of restructuring costs, Spin-Off and separation-related costs, separation-related impacts due to the sale of the Purification and Filtration business, and acquisition-related costs. Solventum defines adjusted operating income as operating income excluding the effects of amortization, restructuring costs, Spin-Off and separation-related costs, certain litigation-related costs, separation-related impacts due to the sale of the Purification and Filtration business, acquisition-related costs and costs related to the planned separation of the Health Information Systems business. Adjusted operating income margin is adjusted operating income divided by the U.S GAAP measure total net sales for the same period. The Company believes adjusted gross margin, adjusted operating income and adjusted operating income margin provide investors with visibility into the Company’s unleveraged, pre-tax operating results and reflects underlying financial performance. However, adjusted gross margin and adjusted operating income should not be construed as inferring that the Company’s future results will be unaffected by the items for which the measure adjusts.

Adjusted diluted earnings per share is not defined under U.S. GAAP. Therefore, it should not be considered a substitute for earnings data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. Solventum defines adjusted diluted earnings per share as net income excluding the after-tax effects of amortization, restructuring costs, Spin-Off and separation-related costs, certain litigation-related costs, separation-related impacts due to the sale of the Purification and Filtration business, acquisition-related costs and costs related to the planned separation of the Health Information Systems business. The Company believes adjusted earnings per share provides investors with improved comparability of underlying operating results and a further understanding and additional transparency regarding how the Company evaluates the business. However, adjusted earnings per share should not be construed as inferring that the Company’s future results will be unaffected by the items for which the measure adjusts.

Solventum Corporation

SUPPLEMENTAL FINANCIAL INFORMATION

NON-GAAP MEASURES – (CONTINUED)*

(Unaudited)

Three months ended June 30, 2026

(Dollars in millions, except per share amounts) Net sales

Cost of sales5

Gross margin %

Operating expenses6

Operating income Operating income margin %

Non-operating expense (income), net7

Income before income taxes Net income attributable to Solventum Diluted EPS Effective tax rate

GAAP $ 2,209 $ 923 58.2 % $ 1,105 $ 181 8.2 % $ 73 $ 108 $ 92 $ 0.53 14.4 %

Non-GAAP adjustments:

Amortization of acquisition-related intangible assets — — — (90) 90 4.1 — 90 76 0.44

Restructuring costs (a)

— (9) 0.4 (33) 42 1.9 — 42 32 0.18

3M spin-off and separation-related costs (b)

— (33) 1.5 (112) 145 6.6 — 145 114 0.65

Certain litigation-related costs (c)

— — — (157) 157 7.1 — 157 119 0.69

Purification and Filtration separation-related (d)

— 1 — 7 (8) (0.4) — (8) (6) (0.04)

Acquisition-related costs(e)

— — — (15) 15 0.7 — 15 11 0.07

Planned separation of Health Information Systems-related (f)

— — — (6) 6 0.3 — 6 4 0.03

Non-GAAP $ 2,209 $ 881 60.1 % $ 701 $ 627 28.4 % $ 73 $ 554 $ 442 $ 2.55 20.2 %

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

Three months ended June 30, 2025

(Dollars in millions, except per share amounts) Net sales

Cost of sales5

Gross margin %

Operating expenses6

Operating income Operating income margin %

Non-operating expense (income), net7

Income before income taxes Net income attributable to Solventum Diluted EPS Effective tax rate

GAAP $ 2,161 $ 986 54.4 % $ 961 $ 214 9.9 % $ 111 $ 103 $ 90 $ 0.51 12.5 %

Non-GAAP adjustments:

Amortization of acquisition-related intangible assets — — — (78) 78 3.6 — 78 67 0.38

Restructuring costs (a)

— (1) 0.1 (7) 8 0.5 — 8 6 0.03

3M spin-off and separation-related costs (b)

— (33) 1.5 (117) 150 6.9 — 150 115 0.66

Certain litigation-related costs (c)

— — — (8) 8 0.4 — 8 6 0.03

Purification and Filtration separation-related (d)

— — — (15) 15 0.7 — 15 12 0.07

Non-GAAP $ 2,161 $ 952 56.0 % $ 736 $ 474 21.9 % $ 111 $ 362 $ 296 $ 1.69 18.3 %

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

(a)2026 restructuring costs primarily related to the Company’s Transform for the Future program. Includes employee termination costs of $11 million and other costs of $31 million, which includes third-party consulting, asset write-downs and compensation for employees dedicated to the program. 2025 restructuring costs primarily relate to the Company’s Solventum Way program. Includes employee termination costs of $9 million and other costs of $(1) million.

(b)Consists of costs specifically incurred in connection with the Company’s separation from 3M.

(c)Consists of charges and recoveries related to certain litigation matters.

(d)2026 activity consists of the profit mark-up from transition support services. 2025 activity consists of costs related to and tax impacts from the separation of the Company’s Purification and Filtration business, including legal, finance and tax advisory.

(e)Integration costs related to the acquisition of Acera Surgical, including amortization of inventory step-up.

(f)Costs related to the planned separation of the Company’s Health Information Systems business.

5 Cost of sales is the combination of cost of product and cost of software and rentals line items from the Condensed Consolidated Statements of Income and represents the total Company’s cost of sales.

6 Operating expenses is the combination of selling, general and administrative expenses and research and development expenses from the Condensed Consolidated Statements of Income and represents the total Company’s other operating expenses.

7 Non-operating expense (income), net is the combination of interest expense, net, and other expense (income), net line items from the Condensed Consolidated Statements of Income and represents the total Company’s non-operating expense.

Solventum Corporation

SUPPLEMENTAL FINANCIAL INFORMATION

NON-GAAP MEASURES – (CONTINUED)*

(Unaudited)

Six months ended June 30, 2026

(Dollars in millions, except per share amounts) Net sales

Cost of sales5

Gross margin %

Operating expenses6

Operating income Operating income margin %

Non-operating expense (income), net7

Income before income taxes Net income attributable to Solventum Diluted EPS Effective tax rate

GAAP $ 4,216 $ 1,833 56.5 % $ 2,121 $ 262 6.2 % $ 138 $ 123 $ 105 $ 0.60 15.0 %

Non-GAAP adjustments:

Amortization of acquisition-related intangible assets — — — (181) 181 4.3 — 181 152 0.87

Restructuring costs (a)

— (10) 0.2 (73) 82 2.0 — 82 63 0.36

3M spin-off and separation-related costs (b)

— (64) 1.5 (244) 308 7.3 — 308 241 1.38

Certain litigation-related costs (c)

— — — (171) 171 4.0 — 171 129 0.74

Purification and Filtration separation-related (d)

— 2 — 10 (12) (0.3) — (12) (9) (0.05)

Acquisition-related costs(e)

— (4) 0.1 (17) 21 0.5 — 21 16 0.09

Planned separation of Health Information Systems-related (f)

— — — (6) 6 0.1 — 6 4 0.02

Non-GAAP $ 4,216 $ 1,755 58.4 % $ 1,441 $ 1,019 24.2 % $ 138 $ 881 $ 702 $ 4.02 20.3 %

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

Six months ended June 30, 2025

(Dollars in millions, except per share amounts) Net sales

Cost of sales5

Gross margin %

Operating expenses6

Operating income Operating income margin %

Non-operating expense (income), net7

Income before income taxes Net income attributable to Solventum Diluted EPS Effective tax rate

GAAP $ 4,231 $ 1,942 54.1 % $ 1,922 $ 367 8.7 % $ 226 $ 141 $ 227 $ 1.30 (61.0) %

Non-GAAP adjustments:

Amortization of acquisition-related intangible assets — — — (159) 159 3.7 — 159 135 0.77

Restructuring costs (a)

— (11) 0.3 (15) 26 0.6 — 26 20 0.11

3M spin-off and separation-related costs (b)

— (60) 1.4 (210) 272 6.4 — 272 209 1.20

Certain litigation-related costs (c)

— — — (27) 27 0.6 — 27 20 0.11

Purification and Filtration separation-related (d)

— — — (31) 31 0.7 — 31 (80) (0.46)

Non-GAAP $ 4,231 $ 1,871 55.8 % $ 1,480 $ 881 20.8 % $ 226 $ 655 $ 530 $ 3.03 19.0 %

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

(a)2026 restructuring costs primarily relate to the Company’s Transform for the Future program. Includes employee termination costs of $16 million and other costs of $66 million, which includes third-party consulting, asset write-downs and compensation for employees dedicated to the program. 2025 restructuring costs primarily related to the Company’s Solventum Way program. Includes employee termination costs of $23 million and other costs of $3 million.

(b)Consists of costs specifically incurred in connection with the Company’s separation from 3M.

(c)Consists of charges and recoveries related to certain litigation matters.

(e)Integration costs related to the acquisition of Acera Surgical, including amortization of inventory step-up.

(f)Costs related to the planned separation of the Company’s Health Information Systems business.

5 Cost of sales is the combination of cost of product and cost of software and rentals line items from the Consolidated Statements of Income and represents the total Company’s cost of sales.

6 Operating expenses is the combination of selling, general and administrative expenses and research and development expenses from the Consolidated Statements of Income and represents the total Company’s other operating expenses.

7 Non-operating expense (income), net is the combination of interest expense, net, loss on debt extinguishment, net, and other expense (income), net line items from the Consolidated Statements of Income and represents the total Company’s non-operating expense.

Solventum Corporation

SUPPLEMENTAL FINANCIAL INFORMATION

NON-GAAP MEASURES – (CONTINUED)*

(Unaudited)

Free Cash Flow (non-GAAP measure):

Free cash flow is not defined under U.S. GAAP. Therefore, it should not be considered a substitute for income or cash flow data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. The Company defines free cash flow as net cash provided by (used in) operating activities less purchases of property, plant and equipment. It should not be inferred that the entire free cash flow amount is available for discretionary expenditures. The Company believes free cash flow is meaningful to investors as it is a useful measure of liquidity and the Company uses this measure as an indication of the strength of the Company and its ability to generate cash. Free cash flow varies across quarters throughout the year. Below find a recap of free cash flow.

(Dollars in millions) Three months ended June 30, Six months ended June 30,

Major GAAP cash flow categories 2026 2025 2026 2025

Net cash provided by operating activities 227 169 38 198

Net cash used in investing activities (87) (110) (164) (224)

Net cash used in financing activities (300) (110) (350) (249)

Free cash flow (non-GAAP measure)

Net cash provided by operating activities 227 169 38 198

Purchases of property, plant and equipment (83) (110) (167) (219)

Free cash flow 144 59 (129) (21)

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum.

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover Page

Aug. 05, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Aug. 05, 2026

Entity Registrant Name

SOLVENTUM CORPORATION

Entity Incorporation, State or Country Code

Entity File Number

001-41968

Entity Tax Identification Number

92-2008841

Entity Address, Address Line One

1750 Yankee Doodle Road

Entity Address, City or Town

Eagan

Entity Address, State or Province

Entity Address, Postal Zip Code

55121

City Area Code

651

Local Phone Number

733-1110

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, Par Value $.01 Per Share

Trading Symbol

SOLV

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Amendment Flag

false

Entity Central Index Key

0001964738

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration